“Specific Detection of HER-2 positive tumors in mice using superparamagnetic relaxometry” is the title of a poster presented by Erika Vreeland, PhD, at the 2017 World Medical Imaging Congress. The poster data, showing high sensitivity and the selective ability of tumor-targeting MagSense nanoparticles to discriminate between HER2-overexpressing and non-overexpressing cancer cells in mice, contribute to the evidence Imagion Biosystems is building in support of the company’s plan for first-in-human clinical trials.
Download the poster “Specific detection of HER-2 positive tumors in mice using superparamagnetic relaxometry (SPMR).”
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)
